Effects of estrogen on cardiovascular injury in ovariectomized female DahlS.Z-Leprfa/Leprfa rats as a new animal model of metabolic syndrome

Hypertension

Volumn 59, Issue 3, 2012, Pages 694-704

  Murase, Tamayo ^a   Hattori, Takuya ^a   Ohtake, Masafumi ^a   Nakashima, Chieko ^b   Takatsu, Miwa ^a   Murohara, Toyoaki ^a   Nagata, Kohzo ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

diastolic dysfunction; estrogen; hypertension; inflammation; metabolic syndrome; myocardial fibrosis; oxidative stress

Indexed keywords

ESTRADIOL; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDITIS; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; ESTROGEN THERAPY; EXPERIMENTAL MODEL; FAT CONTENT; FEMALE; FOOD INTAKE; GENE EXPRESSION; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; HISTOPATHOLOGY; HOMOZYGOSITY; HYPERTENSION; INTRAABDOMINAL FAT; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OVARIECTOMY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; ESTRADIOL; ESTROGENS; FEMALE; HYPERTENSION; METABOLIC SYNDROME X; MYOCARDIAL CONTRACTION; OVARIECTOMY; RATS; RATS, INBRED DAHL; RATS, ZUCKER; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84857542727     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.180976     Document Type: Article

References (53)

1. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111: 1448-1454. (Pubitemid 40396812)
2. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811. (Pubitemid 29266405)
3. Ren J, Kelley RO. Cardiac health in women with metabolic syndrome: clinical aspects and pathophysiology. Obesity (Silver Spring). 2009;17: 1114-1123.
4. Pinto S, Virdis A, Ghiadoni L, Bernini G, Lombardo M, Petraglia F, Genazzani AR, Taddei S, Salvetti A. Endogenous estrogen and acetylcholine- induced vasodilation in normotensive women. Hypertension. 1997;29:268-273. (Pubitemid 27074054)
5. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613. (Pubitemid 28502636)
6. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534. (Pubitemid 36951364)
7. Shinmura K, Nagai M, Tamaki K, Bolli R. Loss of ischaemic preconditioning in ovariectomized rat hearts: possible involvement of impaired protein kinase C phosphorylation. Cardiovasc Res. 2008; 79:387-394.
8. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci U S A. 1992;89: 11259-11263.
9. Koh KK. Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovasc Res. 2002;55:714-726.
10. Gorodeski GI, Yang T, Levy MN, Goldfarb J, Utian WH. Effects of estrogen in vivo on coronary vascular resistance in perfused rabbit hearts. Am J Physiol. 1995;269:R1333-R1338.
11. Khalil RA. Sex hormones as potential modulators of vascular function in hypertension. Hypertension. 2005;46:249-254. (Pubitemid 41099147)
12. Schunkert H, Danser AH, Hense HW, Derkx FH, Kurzinger S, Riegger GA. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation. 1997;95:39-45. (Pubitemid 27029940)
13. Seely EW, Brosnihan KB, Jeunemaitre X, Okamura K, Williams GH, Hollenberg NK, Herrington DM. Effects of conjugated oestrogen and droloxifene on the renin-angiotensin system, blood pressure and renal blood flow in postmenopausal women. Clin Endocrinol (Oxf). 2004;60: 315-321. (Pubitemid 38297121)
14. Stier CT Jr, Chander PN, Rosenfeld L, Powers CA. Estrogen promotes microvascular pathology in female stroke-prone spontaneously hypertensive rats. Am J Physiol Endocrinol Metab. 2003;285:E232-E239. (Pubitemid 36736381)
15. Oestreicher EM, Guo C, Seely EW, Kikuchi T, Martinez-Vasquez D, Jonasson L, Yao T, Burr D, Mayoral S, Roubsanthisuk W, Ricchiuti V, Adler GK. Estradiol increases proteinuria and angiotensin II type 1 receptor in kidneys of rats receiving L-NAME and angiotensin II. Kidney Int. 2006;70:1759-1768. (Pubitemid 44684807)
16. Hattori T, Murase T, Ohtake M, Inoue T, Tsukamoto H, Takatsu M, Kato Y, Murohara T, Nagata K. Characterization of a new animal model of metabolic syndrome: the DahlS.Z-Leprfa/Leprfa rat. Nutr Diab. 2011;1:e1.
17. Murase T, Hattori T, Ohtake M, Abe M, Amakusa Y, Takatsu M, Murohara T, Nagata K. Cardiac remodeling and diastolic dysfunction in DahlS.Z-Leprfa/Leprfa rats: a new animal model of metabolic syndrome. Hypertens Res. Epub ahead of print September 15, 2011.
18. Rooke GA, Feigl EO. Work as a correlate of canine left ventricular oxygen consumption, and the problem of catecholamine oxygen wasting. Circ Res. 1982;50:273-286. (Pubitemid 12168319)
19. Nagata K, Somura F, Obata K, Odashima M, Izawa H, Ichihara S, Nagasaka T, Iwase M, Yamada Y, Nakashima N, Yokota M. AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. Hypertension. 2002;40:168-174. (Pubitemid 34840093)
20. Kato MF, Shibata R, Obata K, Miyachi M, Yazawa H, Tsuboi K, Yamada T, Nishizawa T, Noda A, Cheng XW, Murate T, Koike Y, Murohara T, Yokota M, Nagata K. Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. J Hypertens. 2008;26:1669-1676.
21. Yamada T, Nagata K, Cheng XW, Obata K, Saka M, Miyachi M, Naruse K, Nishizawa T, Noda A, Izawa H, Kuzuya M, Okumura K, Murohara T, Yokota M. Long-term administration of nifedipine attenuates cardiac remodeling and diastolic heart failure in hypertensive rats. Eur J Pharmacol. 2009;615:163-170.
22. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006;47:656-664. (Pubitemid 43740235)
23. Miyachi M, Yazawa H, Furukawa M, Tsuboi K, Ohtake M, Nishizawa T, Hashimoto K, Yokoi T, Kojima T, Murate T, Yokota M, Murohara T, Koike Y, Nagata K. Exercise training alters left ventricular geometry and attenuates heart failure in dahl salt-sensitive hypertensive rats. Hypertension. 2009;53: 701-707.
24. Ahmed MS, Oie E, Vinge LE, Yndestad A, Oystein Andersen G, Andersson Y, Attramadal T, Attramadal H. Connective tissue growth factor: a novel mediator of angiotensin II-stimulated cardiac fibroblast activation in heart failure in rats. J Mol Cell Cardiol. 2004;36: 393-404. (Pubitemid 38316944)
25. Gao Q, Mezei G, Nie Y, Rao Y, Choi CS, Bechmann I, Leranth C, Toran-Allerand D, Priest CA, Roberts JL, Gao XB, Mobbs C, Shulman GI, Diano S, Horvath TL. Anorectic estrogen mimics leptin's effect on the rewiring of melanocortin cells and Stat3 signaling in obese animals. Nat Med. 2007;13:89-94. (Pubitemid 46067391)
26. Mueller SO, Korach KS. Estrogen receptors and endocrine diseases: lessons from estrogen receptor knockout mice. Curr Opin Pharmacol. 2001;1:613-619. (Pubitemid 33586003)
27. Cambotti LJ, Cole FE, Gerall AA, Frohlich ED, MacPhee AA. Neonatal gonadal hormones and blood pressure in the spontaneously hypertensive rat. Am J Physiol. 1984;247:E258-E264. (Pubitemid 14064261)
28. Sharkey LC, Holycross BJ, Park S, Shiry LJ, Hoepf TM, McCune SA, Radin MJ. Effect of ovariectomy and estrogen replacement on cardiovascular disease in heart failure-prone SHHF/Mcc- facp rats. J Mol Cell Cardiol. 1999;31:1527-1537. (Pubitemid 29361119)
29. Sasaki T, Ohno Y, Otsuka K, Suzawa T, Suzuki H, Saruta T. Oestrogen attenuates the increases in blood pressure and platelet aggregation in ovariectomized and salt-loaded Dahl salt-sensitive rats. J Hypertens. 2000;18:911-917. (Pubitemid 30459493)
30. Farhat MY, Chen MF, Bhatti T, Iqbal A, Cathapermal S, Ramwell PW. Protection by oestradiol against the development of cardiovascular changes associated with monocrotaline pulmonary hypertension in rats. Br J Pharmacol. 1993;110:719-723. (Pubitemid 23279284)
31. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res. 2002;53:688-708. (Pubitemid 34175262)
32. Ricchiuti V, Lian CG, Oestreicher EM, Tran L, Stone JR, Yao T, Seely EW, Williams GH, Adler GK. Estradiol increases angiotensin II type 1 receptor in hearts of ovariectomized rats. J Endocrinol. 2009;200: 75-84.
33. Fisman EZ, Tenenbaum A, Shapira I, Motro M, Pines A. The acute effects of sublingual estradiol on left ventricular diastolic function in normotensive and hypertensive postmenopausal women. Maturitas. 1999; 33:145-152. (Pubitemid 29509935)
34. Langrish JP, Mills NL, Bath LE, Warner P, Webb DJ, Kelnar CJ, Critchley HO, Newby DE, Wallace WH. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension. 2009;53:805-811.
35. Dhuper S, Abdullah RA, Weichbrod L, Mahdi E, Cohen HW. Association of obesity and hypertension with left ventricular geometry and function in children and adolescents. Obesity (Silver Spring). 2011; 19:128-133.
36. Pedram A, Razandi M, Lubahn D, Liu J, Vannan M, Levin ER. Estrogen inhibits cardiac hypertrophy: role of estrogen receptor- to inhibit calcineurin. Endocrinology. 2008;149:3361-3369. (Pubitemid 351919609)
37. Matsui H, Ando K, Kawarazaki H, Nagae A, Fujita M, Shimosawa T, Nagase M, Fujita T. Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension. 2008;52: 287-294.
38. Grohe C, Kahlert S, Lobbert K, Meyer R, Linz KW, Karas RH, Vetter H. Modulation of hypertensive heart disease by estrogen. Steroids. 1996;61: 201-204. (Pubitemid 26144423)
39. Zhou L, Shao Y, Huang Y, Yao T, Lu LM. 17-Estradiol inhibits angiotensin II-induced collagen synthesis of cultured rat cardiac fibroblasts via modulating angiotensin II receptors. Eur J Pharmacol. 2007; 567:186-192. (Pubitemid 46976891)
40. Zhan E, Keimig T, Xu J, Peterson E, Ding J, Wang F, Yang XP. Dose-dependent cardiac effect of oestrogen replacement in mice postmyocardial infarction. Exp Physiol. 2008;93:982-993. (Pubitemid 352000276)
41. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, Imaizumi T. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension. 2004;43:739-745. (Pubitemid 38405580)
42. Cushman M. Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation. Am J Cardiol. 2002;90(suppl):7F-10F. (Pubitemid 34775145)
43. Yamaleyeva LM, Pendergrass KD, Pirro NT, Gallagher PE, Groban L, Chappell MC. Ovariectomy is protective against renal injury in the high-salt-fed older mRen2. Lewis rat. Am J Physiol Heart Circ Physiol. 2007;293:H2064-H2071. (Pubitemid 47605842)
44. Cid MC, Schnaper HW, Kleinman HK. Estrogens and the vascular endothelium. Ann N Y Acad Sci. 2002;966:143-157. (Pubitemid 34729170)
45. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114:1752-1761. (Pubitemid 40385531)
46. White RE, Gerrity R, Barman SA, Han G. Estrogen and oxidative stress: A novel mechanism that may increase the risk for cardiovascular disease in women. Steroids. 2010;75:788-793.
47. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol. 2002;34:379-388. (Pubitemid 37163454)
48. 2+]i in female rat cardiac myocytes. Clin Exp Pharmacol Physiol. 2003;30:489-494. (Pubitemid 36836566)
49. Wassmann S, Baumer AT, Strehlow K, van Eickels M, Grohe C, Ahlbory K, Rosen R, Bohm M, Nickenig G. Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats. Circulation. 2001;103:435-441. (Pubitemid 32105985)
50. Nagata K. Mineralocorticoid antagonism and cardiac hypertrophy. Curr Hypertens Rep. 2008;10:216-221.
51. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res. 2002;91:406-413. (Pubitemid 35034208)
52. Xu Y, Arenas IA, Armstrong SJ, Davidge ST. Estrogen modulation of left ventricular remodeling in the aged heart. Cardiovasc Res. 2003;57: 388-394. (Pubitemid 36144217)
53. Dias DP, Oliveira M, Salgado HC, Fazan R Jr. Ovariectomy does not affect the cardiac sympathovagal balance of female SHR but estradiol does. Braz J Med Biol Res. 43:969-975.